First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20

AnaptysBio will spin off First Tracks Biotherapeutics in a 1-for-1 distribution to shareholders at 12:01 a.m. NYC on April 20, 2026 (record date April 6, 2026); the SEC declared the registration statement effective on April 1, 2026. First Tracks (Delaware, pharma, HQ San Diego) is expected to begin regular-way trading on Nasdaq as TRAX on April 20, with a when-issued market under TRAXV from April 6; completion remains subject to conditions in the information statement.

Analysis

The corporate separation will create two investible risk profiles and a temporary liquidity fracture that typically generates 3–10% price dispersion between entitlement and ex‑distribution lines in the first 2–4 weeks. Market makers and event‑arbitrage desks will be active: expect widened spreads, elevated financing demand, and a meaningful bid for the security that best matches quant/mandate fit (pure‑play therapeutic vs diversified parent).

Second‑order winners are index/ETF rebalancers and specialist biotech funds that can only hold pure therapeutics — they may rotate capital into the spun‑off entity and out of the parent over a 1–3 month window, pressuring the parent’s free float. Conversely, corporate buyers (mid‑cap pharma looking for bolt‑on assets) become more likely acquirers once the asset sits as a standalone, making a 6–18 month M&A takeout a realistic upside catalyst.

Key risks: executional frictions (transfer agent/logistics), early insider selling, and limited options liquidity can create sudden 15–30% moves within days. Over a 12‑month horizon, clinical or regulatory setbacks for the underlying therapeutic program remain the dominant value driver and could erase spin‑driven gains quickly if trial readouts disappoint or if the new company needs equity financing.

The consensus behavioral error will be treating the separation as value realization rather than a rerating event; markets often misprice governance and capital‑allocation risk post spin. Monitor when‑issued/ex‑distribution spreads and initial insider lockup windows — those two metrics will tell you whether this is a transient technical dislocation or the start of a structural revaluation.

Key Decisions for Investors

• Relative-value arbitrage: Monitor the when-issued vs ex‑distribution spread between ANAB and the spun entity; if entitlement pricing >3% richer than ex line and financing cost <4%, buy the cheaper line and short the richer line for a 2–6 week capture (target 3–8% gross, stop‑loss 12%).
• Event long (6–18 months): Long ANAB post‑settlement size (5% position) to capture potential parent rerating if management retains high‑value programs; hedge with a 25–30% notional put hedge or buy 1–2 month out-of-the-money puts after any >30% pop (as tail protection).
• M&A play: Buy the spun‑off pure‑play therapeutic on launch if >50% of free float remains retail and if trading volume <100k/day — small float increases takeover probability; target 25–40% upside within 6–18 months, set liquidity exit if volume stays <30k/day after 90 days.
• Options liquidity play: If options are available on ANAB, sell short‑dated covered calls (30–45 days) post‑settlement to harvest elevated IV from event uncertainty; expect 3–6% premium returns per month with downside defined by underlying stock move.
• Risk control: Set alerts for insider selling and any equity raise announcements in the first 12 months; if either occurs, reduce exposure by 50% immediately given dilution and signalling risks.